Acne, mental health and isotretinoin: disentangling disease burden, treatment effects and psychiatric risk

Acne vulgaris is among the most common chronic inflammatory skin conditions worldwide. It is consistently associated with depression, anxiety, shame, social withdrawal and impaired quality of life - factors that are frequently underestimated in routine clinical practice. Simultaneously, isotretinoin, the most effective systemic treatment for severe or scarring acne, remains at the centre of a longstanding debate about psychiatric safety. This narrative review examines evidence on acne--related psychological burden, the bidirectional interaction between acne and mental health, and contemporary data on psychiatric outcomes during isotretinoin therapy. Pooled analyses confirm that patients with acne have substantially elevated rates of depressive symptoms (approximately 22%), anxiety (approximately 29%) and suicidal ideation (approximately 12%), often disproportionate to physician-rated lesion counts. In contrast, the best available population-level evidence does not support a generalized increase in suicide risk or psychiatric disorders among people using isotretinoin; some data suggest a reduction in rates of suicide attempts in the years following treatment. Pharmacovigilance signals persist but are hypothesis-generating rather than causal, and principally support structured monitoring in vulnerable subgroups. The core clinical task is not to determine whether isotretinoin is universally safe or dangerous, but to distinguish three concurrent forces: psychosocial burden attributable to acne itself, pre-existing psychiatric vulnerability, and rare treatment-emergent events. A pragmatic monitoring model that integrates baseline psychiatric screening, longitudinal follow-up and shared decision making is more useful than binary risk labelling. Addressing visible inflammation and invisible psychiatric burdens together represents the standard to which acne care should aspire.